Larimar Therapeutics, Inc. LRMR

LRMR Quotes by TradingView
Institutional shares held 66.7 Million
500K calls
61.2K puts
Total value of holdings $157M
$1.17M calls
$143K puts
Market Cap $82.2M
43,269,200 Shares Out.
Institutional ownership 154.09%
# of Institutions 124

Quarterly Institutional Activity in LRMR

Shares Bought
Shares Sold
View Transactions

Top Institutions Holding LRMR

View all
View all

Latest Institutional Activity in LRMR

Top Purchases

Q1 2025
Rhumbline Advisers Shares Held: 65K ($124K)
8.82K Shares purchased
15.69% Added
Q4 2024
Janus Henderson Group PLC Shares Held: 6.44M ($12.2M)
876K Shares purchased
15.74% Added
Q4 2024
Blue Owl Capital Holdings LP Shares Held: 4.65M ($8.84M)
486K Shares purchased
11.67% Added
Q4 2024
Adage Capital Partners Gp, L.L.C. Shares Held: 2.1M ($3.99M)
399K Shares purchased
23.47% Added
Q4 2024
Alyeska Investment Group, L.P. Shares Held: 984K ($1.87M)
274K Shares purchased
38.57% Added
View All Buyers

Top Sells

Q1 2025
Sg Americas Securities, LLC Shares Held: 15K ($28.5K)
4.42K Shares sold
22.78% Reduced
Q1 2025
Assenagon Asset Management S.A. Shares Held: 218K ($415K)
1.55K Shares sold
0.71% Reduced
Q4 2024
Woodline Partners LP Shares Held: 623K ($1.18M)
622K Shares sold
49.97% Reduced
Q4 2024
Millennium Management LLC Shares Held: 255K ($484K)
509K Shares sold
66.62% Reduced
Q4 2024
Deutsche Bank Ag\ Shares Held: 44.1K ($83.7K)
238K Shares sold
84.38% Reduced
View All Sellers

About LRMR

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

LRMR Chart by TradingView
LRMR Fundamental Data by TradingView

Insider Transactions at LRMR

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
Jan 22 2025
Michael Celano Chief Financial Officer
BUY
Grant, award, or other acquisition
Direct
34,185 +16.1%
-
Jan 22 2025
Carole Ben Maimon President and CEO
BUY
Grant, award, or other acquisition
Direct
91,000 +19.03%
-
Jan 22 2025
Russell Clayton Chief Medical Officer
BUY
Grant, award, or other acquisition
Direct
23,306 +33.72%
-
Jan 22 2025
Gopi Shankar Chief Development Officer
BUY
Grant, award, or other acquisition
Direct
23,306 +31.45%
-
Feb 16 2024
Thomas Edward Hamilton Director
BUY
Open market or private purchase
Direct
57,208 +9.2%
$457,664 $8.74 P/Share
Feb 16 2024
James E Flynn Director
BUY
Open market or private purchase
Indirect
4,290,617 +21.03%
$34,324,936 $8.74 P/Share
Feb 14 2024
Frank E Thomas Director
BUY
Open market or private purchase
Direct
2,000 +50.0%
$22,000 $11.0 P/Share
Jan 17 2024
Carole Ben Maimon President and CEO
BUY
Grant, award, or other acquisition
Direct
66,125 +16.57%
-
Jan 17 2024
Russell Clayton Chief Medical Officer
BUY
Grant, award, or other acquisition
Direct
22,500 +50.0%
-
Jan 17 2024
Michael Celano Chief Financial Officer
BUY
Grant, award, or other acquisition
Direct
31,250 +17.83%
-
Dec 07 2023
Gopi Shankar Chief Development Officer
BUY
Open market or private purchase
Direct
5,000 +50.0%
$15,000 $3.73 P/Share
May 17 2023
Joseph Truitt Director
BUY
Open market or private purchase
Direct
2,750 +50.0%
$8,250 $3.73 P/Share
May 17 2023
Carole Ben Maimon President and CEO
BUY
Open market or private purchase
Direct
5,000 +1.84%
$15,000 $3.7 P/Share
May 17 2023
Michael Celano Chief Financial Officer
BUY
Open market or private purchase
Direct
5,000 +4.25%
$15,000 $3.73 P/Share
Jan 31 2023
Carole Ben Maimon President and CEO
BUY
Grant, award, or other acquisition
Direct
205,000 +43.91%
-
Jan 31 2023
Michael Celano Chief Financial Officer
BUY
Grant, award, or other acquisition
Direct
76,000 +41.36%
-
Sep 16 2022
Thomas Edward Hamilton Director
BUY
Open market or private purchase
Direct
317,460 +38.48%
$952,380 $3.15 P/Share
Sep 16 2022
James E Flynn Director
BUY
Open market or private purchase
Indirect
11,111,108 +40.28%
$33,333,324 $3.15 P/Share
Sep 16 2022
Michael Celano Chief Financial Officer
BUY
Open market or private purchase
Direct
31,746 +50.0%
$95,238 $3.15 P/Share
View All Transactions

Last 12 Months Summary

Buy / Acquisition
172K Shares
From 4 Insiders
Grant, award, or other acquisition 172K shares
Sell / Disposition
0 Shares
From 0 Insiders

Track Institutional and Insider Activities on LRMR

Follow Larimar Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells LRMR shares.

Notify only if
Any

Insider Trading

Get notified when an Larimar Therapeutics, Inc. insider buys or sells LRMR shares.

Notify only if
Any
Any
P - Open market or private purchase×
S - Open market or private sale×
V - Transaction voluntarily reported earlier than required×
A - Grant, award, or other acquisition×
D - Sale (or disposition) back to the issuer×
F - Payment of exercise price or tax liability×
I - Discretionary transaction×
M - Exercise of conversion of derivative security×
C - Conversion of derivative security×
E - Expiration of short derivative position×
H - Expiration (or cancellation) of long derivative position with value received×
O - Exercise of out-of-the-money derivative securities×
X - Exercise of in-the-money or at-the-money derivatives securities×
G - Bona fide gift×
L - Small Acquisition×
W - Acquisition or disposition by will or laws×
Z - Deposit into or withdrawal from voting trust×
J - Other acquisition or disposition×
K - Transaction in equity swap or similar instrument×
U - Disposition due to a tender of shares in a change of control transaction×
20 item(s) selected

News

Receive news related to Larimar Therapeutics, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on LRMR